# Fish oil (EPA) for cancer weight loss

Source: https://onco.cc/technologies/omega3-epa-cachexia/  
OnCo record `omega3-epa-cachexia` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fish oil rich in EPA was expected to slow cancer-related muscle wasting by damping inflammation. Randomised trials and a Cochrane review found no convincing effect on weight or survival, though fish oil is safe and sits comfortably inside general nutritional support.

## Summary

Eicosapentaenoic acid (EPA) inhibits the inflammatory cascade (IL-6, TNF, proteolysis-inducing factor) implicated in cancer cachexia, and early uncontrolled studies in pancreatic cancer were encouraging. A 2007 Cochrane review of randomised trials found insufficient evidence that oral EPA improves weight, lean mass, quality of life or survival compared with placebo or standard nutritional support; the largest trials showed no benefit. Adherence to the fishy supplements is poor in anorexic patients. EPA-enriched oral nutritional supplements remain an option within dietitian-led nutrition therapy, and ESPEN guidance considers them for patients on chemotherapy at risk of weight loss, but they are not a treatment for established cachexia, for which multimodal programmes and new drugs such as GDF-15 blockade are being tested.

## Fields

- Kind: Technology
- Status: phase-2
- Last checked: 2026-09-10
- Tags: complementary; supportive-care; evidence:insufficient
- Principle: EPA competes with arachidonic acid, reducing pro-inflammatory eicosanoids and cytokine-driven muscle proteolysis; the effect in patients is too small to change body weight.
- Strengths: Safe, well tolerated at usual doses; Reasonable component of nutritional support
- Limitations: No effect on weight or survival in Cochrane review; Poor adherence; Trials heterogeneous

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Eicosapentaenoic_acid
- Cochrane: eicosapentaenoic acid (EPA, an omega-3 fatty acid) for cancer cachexia (2007): https://doi.org/10.1002/14651858.CD004597.pub2

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/)
- terms: [Cancer cachexia](https://onco.cc/terms/cachexia/), [Sarcopenia](https://onco.cc/terms/sarcopenia/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/)
- key papers: [Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia](https://onco.cc/key-papers/paper-dewey-cochrane-database-syst-rev/)
- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/omega3-epa-cachexia.json